Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-Label, Flexible-Dose Vortioxetine
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 14 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Feb 2019.
- 14 Dec 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
- 14 Dec 2016 Status changed from not yet recruiting to recruiting.